Accessibility Menu
Optiscan Imaging logo

Optiscan Imaging(ASX) OIL

Market CapA$177.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-13%
5 Year-22%
1 Year+104%
1 Month+10%
A$0.17
-5.56%
-0.01Today
Optiscan Imaging last closing stock price
MetricPriceDate
Last closeAUD 0.172026-08-14
Optiscan Imaging stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.172026-08-07
1 month+9.68%AUD 0.162026-07-15
3 month+61.9%AUD 0.112026-05-15
Year to date+70%AUD 0.102025-12-31
1 year+103.77%AUD 0.082025-08-14
3 year+122.29%AUD 0.082023-08-15
5 year-22.36%AUD 0.222021-08-13
Since inception-12.66%AUD 0.191997-08-11

Optiscan Imaging Financials at a Glance

Market Cap

A$177.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$6.25M

Net Income (TTM)

-A$12.31M

EPS (TTM)

-A$0.01

P/E Ratio

-20.48

Dividend

A$0.00

Beta (Volatility)

-0.21 (Low)

Price

A$0.17

Volume

429,943

Open

A$0.18

Previous Close

A$0.17

Daily Range

A$0.16 - A$0.18

52-Week Range

A$0.08 - A$0.20

Estimated Earnings Date

Feb 25, 2026

OIL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Optiscan Imaging

Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across clinical and pre-clinical settings globally. The company is known for its innovative FIVE2 (ViewnVivo) system, a compact confocal endomicroscope, and is actively developing the InVivage device for cancer screening and surgical procedures.

Products and Services
  • FIVE2 (ViewnVivo) system for clinical and research applications
  • InVivage device aimed at cancer screening and surgical use
  • Confocal microscopy technology for various medical applications
Growth Outlook
  • Strong demand for advanced imaging solutions in healthcare
  • Expansion into international markets, including Germany
  • Ongoing development of innovative products to enhance market position
Financial Highlights
  • Recent quarterly revenue of AUD 339,227, showing potential for growth
  • Cash and cash equivalents increased to AUD 17.7 million, providing liquidity
  • Current ratio of 14.01 indicates strong short-term financial health
Optiscan Imaging Limited is positioned in the healthcare sector, focusing on advanced imaging technologies that cater to both clinical and research needs. The company's flagship product, the FIVE2 system, is gaining traction in various medical fields, while the InVivage device is expected to enhance cancer screening capabilities. The growth outlook appears promising, driven by increasing demand for innovative imaging solutions and the company's strategic expansion into international markets. Recent financial data indicates a revenue of AUD 339,227 for the latest quarter, reflecting the potential for future growth. Additionally, a significant increase in cash reserves to AUD 17.7 million enhances the company's liquidity, allowing for continued investment in research and development. With a current ratio of 14.01, Optiscan demonstrates strong short-term financial health, positioning itself well to capitalize on emerging opportunities in the medical imaging market. The combination of innovative products, a solid financial foundation, and a focus on growth makes Optiscan Imaging Limited an intriguing option for potential investors interested in the healthcare technology sector.
AI Generated • Jul 28, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Camile Farah, PhD

Website

www.optiscan.com

Headquarters

Mulgrave, VIC 3170, AU

OIL Financials

Key Financial Metrics (TTM)

Gross Margin

56.35%

Operating Margin

-672.06%

Net Income Margin

-571.53%

Return on Equity

-49.32%

Return on Capital

-67.13%

Return on Assets

-29.39%

Earnings Yield

-4.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$177.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.04B

Volume

429.94K

Avg. Volume

262.66K

Financials (TTM)

Gross Profit

A$5.02M

Operating Income

-A$13.49M

EBITDA

-A$13.34M

Operating Cash Flow

-A$12.44M

Capital Expenditure

-A$316.31K

Free Cash Flow

-A$12.76M

Cash & ST Invst.

A$17.71M

Total Debt

A$2.74M

Optiscan Imaging Performance Analysis

Optiscan Imaging annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 1,013,039N/A
20232023-06-30AUD 1,680,18065.9%
20242024-06-30AUD 1,155,604-31.2%
20252025-06-30AUD 951,948-17.6%
Optiscan Imaging sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30385.7%
Q22024-12-3127.4%
Q42025-06-30-66.1%
Q22025-12-31-64.1%
Optiscan Imaging annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.013.0%
20242024-06-30AUD -0.015.8%
20252025-06-30AUD -0.012.7%
Optiscan Imaging sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3027.9%
Q22024-12-319.7%
Q42025-06-30-67.9%
Q22025-12-3123.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$339.23K

-24.5%

Gross Profit

-A$17.90K

-143.2%

Gross Margin

-5.28%

N/A

Market Cap

A$177.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$22.19M

N/A

Employees

8

N/A

Net Income

-A$3.40M

+1.8%

EBITDA

-A$4.57M

-29.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$17.71M

+29.7%

Total Debt

A$2.74M

+504.3%

Accounts Receivable

A$3.18M

+150.4%

Inventory

A$1.80M

-5.9%

Long Term Debt

A$2.49M

+3072.2%

Short Term Debt

A$257.30K

-31.5%

Return on Assets

-29.39%

N/A

Return on Invested Capital

-37.01%

N/A

Free Cash Flow

-A$4.30M

-16.8%

Operating Cash Flow

-A$4.13M

-13.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVU.AXNanoveu Limited
A$0.07-4.17%
AXE.AXArcher Materials Limited
A$0.23+0.00%
SKK.AXStakk Limited
A$0.02+0.00%
IOD.AXIODM Limited
A$0.09-4.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About OIL

What is the current price of Optiscan Imaging?

Optiscan Imaging is trading at A$0.17 per share.

What is the 52-week range for Optiscan Imaging?

Over the past 52 weeks, Optiscan Imaging has traded between A$0.08 and A$0.20.

How much debt does Optiscan Imaging have?

As of the most recent reporting period, Optiscan Imaging reported total debt of A$1.48M.

How much cash does Optiscan Imaging have on hand?

Optiscan Imaging reported A$4.55M in cash and cash equivalents in its most recent financial results.

What is Optiscan Imaging’s dividend yield?

Optiscan Imaging does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services